Synlab has collaborated with genomic and theranostic firm OncoDNA to offer the OncoDeep biomarker test for cancer therapy selection in Germany.
As part of the collaboration, Synlab Laboratories in Germany will have access to the OncoDeep test to perform comprehensive testing of solid tumours and provide support for oncologists.
The test is based on the analysis of more than 600 genes, as well as the measurement of genomic signatures, such as loss of heterozygosity (LOH), tumour mutational burden (TMB), homologous recombination deficiency (HRD) and microsatellite instability (MSI).
